Aprea logo 445pt.png
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
September 20, 2021 16:15 ET | Aprea Therapeutics
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
September 14, 2021 08:00 ET | Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
August 12, 2021 16:15 ET | Aprea Therapeutics
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
August 12, 2021 06:00 ET | Aprea Therapeutics
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
August 05, 2021 17:00 ET | Aprea Therapeutics
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
July 21, 2021 08:00 ET | Aprea Therapeutics
58% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Aprea logo 445pt.png
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 16, 2021 08:00 ET | Aprea Therapeutics
37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and...
Aprea logo 445pt.png
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
May 21, 2021 06:00 ET | Aprea Therapeutics
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
May 18, 2021 06:00 ET | Aprea Therapeutics
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
May 06, 2021 16:15 ET | Aprea Therapeutics
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...